Prime editing emerges as a versatile and safer alternative to traditional CRISPR technology, enabling precise genome modifications without double-stranded DNA breaks. Biochemist David Liu's development of prime editing and its advanced form, twin prime editing, expands the ability to edit longer sequences critical for diseases caused by pathogenic repeats. Notably, recent work demonstrated the delivery of prime editors via engineered virus-like particles to correct retinal degeneration in mice. While prime editing reduces off-target mutations compared to earlier genome editing tools, recent findings urge continued scrutiny of editing accuracy as clinical applications increase.